NCT07035041 - A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

May 22, 2025

Primary Completion Date

July 30, 2026

Study Completion Date

December 31, 2026

Conditions

UC - Ulcerative ColitisModerately to Severely Active Ulcerative Colitis

Interventions

DRUG

D-2570

Subjects will then be randomized in a 1:1:1 ratio to D-2570 or placebo . They will enter the study treatment period and take the assigned investigational product once daily for 12 consecutive weeks.

DRUG

Placebo

Subjects will then be randomized in a 1:1:1 ratio to D-2570 or placebo . They will enter the study treatment period and take the assigned investigational product once daily for 12 consecutive weeks.

Trial Locations (1)

310016

RECRUITING

Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, Hangzhou